Thursday, April 5th • 6AM – 7PM
Radio One Detroit and St. Jude Children’s Research Hospital are partnering once again for the 4th Annual Radio Cares for St. Jude Kids Radiothon.
Last year, despite the difficult economy and deep unemployment that troubled our city and the entire nation our listeners helped raise nearly $50,000 for this very worthwhile cause!
Join us again this year as we partner to help the children of St. Jude.
If you would like to make a donation to this amazing cause, click on the link below or call us on Thursday, April 5th from 6am – 7pmto pledge your support. St. Jude has been improving and saving children’s lives for almost 50 years and they continue that tradition of excellence today. For more information on St. Jude Children’s Hospital, click on the more information link below.
To Donate by Phone, dial (800) 411-9898 (04/05/12 only)
St. Jude Children’s Research Hospital
- St. Jude Children’s Research Hospital® opened in 1962 and was founded by the late entertainer Danny Thomas. Its mission is to find cures for children with cancer and other catastrophic diseases through research and treatment. St. Jude has treated children from all 50 states and from around the world.
- No family ever pays St. Jude for anything.
- In 1962, the survival rate for acute lymphoblastic leukemia (ALL), the most common form of childhood cancer, was 4 percent. Today, the survival rate for this once deadly disease is 94 percent, thanks to research and treatment protocols developed at St. Jude.
- The daily operating cost for St. Jude is $1.7 million, which is primarily covered by public contributions.
- During the past five years, 81 cents of every dollar received has supported the research and treatment at St. Jude.
- St. Jude has treated children from all 50 states and from around the world.
- On average, 7,800 active patients visit the hospital each year, most of whom are treated on an outpatient basis.
- St. Jude maintains 78 inpatient beds and treats upwards of 260 patients each day.
- St. Jude is the first and only pediatric cancer center to be designated as a Comprehensive Cancer Center by the National Cancer Institute.
- In 2011 and 2012, St. Jude Children’s Research Hospital was named one of the country’s “100 Best Companies to Work For,” by FORTUNE magazine.
- St. Jude is the first institution established for the sole purpose of conducting basic and clinical research and treatment into catastrophic childhood diseases, mainly cancer.
- St. Jude was the first pediatric cancer research institution to place doctors, scientists and patients “all under one roof,” creating a worldwide model for “bench-to-bedside” research and treatment of childhood cancers and other life-threatening diseases.
- St. Jude has developed protocols that have helped push overall survival rates for childhood cancers from less than 20 percent when the hospital opened in 1962 to 80 percent today.
- St. Jude has 2.5 million square feet of research, clinical and administrative space dedicated to finding cures and saving children.
- St. Jude revolutionized pediatric cancer treatment around the world with its groundbreaking use of a combination of chemotherapy, radiation and surgery to treat childhood cancers.
- Peter C. Doherty, PhD, of the St. Jude Immunology department, won the Nobel Prize for Physiology or Medicine in 1996. He shares the award with Rolf M. Zinkernagel, MD, of the University of Zurich. Their findings have led to breakthroughs in the understanding and treatment of viral infections and cancers, and in the development of organ transplant procedures and vaccines.
- St. Jude patients are referred by a physician, and generally have a disease currently under study and are eligible to be enrolled in a current research protocol or clinical research trials.
- In addition to childhood cancers, St. Jude researchers and doctors are treating children with genetic immune defects and pediatric AIDS, and are using new drugs and therapies to fight infections.
- The hospital’s International Outreach Program transfers the progress achieved in the treatment of childhood cancer in developed countries to those with limited resources. As of January 2012, St. Jude has 18 partner sites in 14 countries, and more than 29,000 registered users from 182 countries have accessed Cure4Kids.org, an Internet-based distance learning initiative. In addition, St. Jude trains thousands of medical professionals around the world through consultations, faculty visits to St. Jude and Cure4Kids.org.
- The medical and scientific staff published more than 700 articles in academic journals in 2011, more than any other pediatric cancer research center in theUnited States. St. Jude’s researchers are published and cited more often in high impact publications than any other private pediatric oncology institution inAmerica.
- St. Jude was the first institution to produce a cure for sickle cell disease with a bone marrow transplant and has one of the largest pediatric sickle cell disease programs in the country.
- St. Jude is a World Health Organization Collaborating Center for Studies on the Ecology of Influenza Viruses in Animals and Birds.
- The St. Jude faculty includes three National Academy of Sciences members: Peter C. Doherty, PhD, of Immunology; Charles Sherr, MD, PhD, of Tumor Cell Biology; and Robert Webster, PhD, of Infectious Diseases. Sherr and Brenda Schulman, PhD, Structural Biology, hold the coveted title of Howard Hughes Medical Institute Investigators.
- The St. Jude faculty includes five members of the Institute of Medicine of the National Academy of Sciences: William E. Evans, PharmD, St. Jude director and chief executive officer; Arthur Nienhuis, MD, of Hematology and former director and CEO; Charles Sherr, MD, PhD, of Tumor Cell Biology; Peter C. Doherty, PhD, of Immunology; and Mary Relling, PharmD, chair of St. Jude Pharmaceutical Sciences.
- St. Jude is the national coordinating center for the National Cancer Institute-funded Pediatric Brain Tumor Consortium and the Children’s Cancer Survivor Study. St. Jude also is the coordinating center for a national study of sickle cell disease treatment funded by the National Heart, Lung and Blood Institute.